SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about slowing growth, content quality and competition; recent leadership changes and layoffs add to the debate. Bulls see pessimism as overdone, while bears expect further weakness, leaving sentiment sharply divided ahead of the report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Heavy buying and a sharp rebound have fueled speculation about a potential buyout or imminent company news, but neither has been confirmed. The main catalyst in discussion is the Phase 3 REGAL trials pending final analysis after the last disclosed count of 78 of 80 events; bullish traders read the CEOs optimistic anniversary post as encouraging, while skeptics point to the lack of new trial news and caution that the move may reflect trading activity.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound above recent technical levels has traders discussing a possible breakout and short covering, though no specific new catalyst is confirmed. Bulls are also anticipating DM1 and FSHD siRNA readouts, while some caution that the move may reflect broader biotech strength or prove temporary.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs shares fell despite a third-quarter earnings beat and a new buyback, as traders focused on the narrowed full-year profit outlook and unchanged midpoint. The reaction is split between dip buyers citing cash generation and repurchases, and bears who see the outlook and softer sales as outweighing those positives.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly beat and raised 2026 outlook are being overshadowed by a sharp selloff. Traders debate whether it is a sell-the-news reaction after expectations ran high or a response to rising costs, weaker cash conversion and an insurance loss, while some point to strong orders as evidence demand remains robust.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention alongside analyst upgrades. Traders are divided over the modest placebo-adjusted symptom improvement and concerns about discontinuations and agitation, with some viewing the data as a positive proof of concept and others arguing the rally may fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is drawing attention as traders watch for Q3 results to confirm continued growth in high-margin ASCENIV amid weakness in BIVIGAM, with the recent move around its 200-day average adding to the recovery discussion. Bulls point to ASCENIV and share repurchases, while skeptics cite uncertain growth and lingering concerns from the Culper short report and related litigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Genenta Stock Rises Pre-Market After Cell Therapy Improves Survival In Certain Tumor Patients

Equity

The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.


GNTA Stock Skyrockets 300% Pre-Market Toward Record Highs: What’s Driving The Super Rally?

Genenta Science SpA operates as a biotechnology company, which engages in strategic consolidation focused on acquiring majority or full ownership of privately held, established companies operating in Italian national security-regulated sectors. Its activities and acquisition strategy span aerospace, defense, national security, including cybersecurity, and biotechnology and biosecurity. The company was founded by Pierluigi Paracchi, Bernhard Gentner, and Luigi Naldini on July 24, 2014 and is headquartered in Milan, Italy.

Genenta Science SpA - ADR

Neutral Sentiment

<ul class="summary-bullets"><li>Glioblastoma multiforme (GBM) is an aggressive, fast-growing brain and spinal cord tumor that generally has a poor prognosis with a low median survival rate.</li><li>Patients treated with Temferon in the study had a median overall survival remains at 17 months, consistent with prior findings.</li><li>A patient in the study also reached three years of survival following Temferon administration, the company said.</li></ul>Shares of Genenta Science (GNTA) soared 10% in the pre-market session on Monday after the company announced long-term survival trends from the study of its cell therapy in the treatment of some newly diagnosed glioblastoma multiforme (GBM) patients.Glioblastoma multiforme (GBM) is an aggressive, fast-growing brain and spinal cord tumor that generally has a poor prognosis with a low median survival rate. Genenta is studying Temferon, an experimental cell therapy, in the patient population.<h2 class="st-heading-2">What Does The Study Show?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193229/0/en/Genenta-Reports-Long-Term-Survival-Trends-and-Immune-Findings-in-Brain-Tumor-GBM-Trial.html">said</a> that 25 patients have been treated with Temferon as of November 21, and 44% of patients have reached 18-month survival. This marks an increase from April, when the company had announced that 38% of patients had reached 18-month survival.Median overall survival remains at 17 months, consistent with prior findings, while the two-year survival rate continues to be 29%, the company said, while adding that median overall survival on standards of care is typically 13-15 months with a two-year survival rate of about 14%.A patient in the study also reached three years of survival following Temferon administration, the company said. Overall, the study also provided early immune observations on Temferon’s behavior within the tumor microenvironment, it added. The observations must now be confirmed in larger, controlled studies.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GNTA jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:584/55;" src="data:image/png;base64,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" width="584" height="55"><figcaption>GNTA’s Sentiment Meter and Message Volume as of 6:15 a.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/GNTA">GNTA stock</a> is down by 61% this year and by about 65% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/deere-q4-earnings-seen-under-pressure-amid-weak-farmer-sentiment/cL5bdq0REfH">Deere Q4 Earnings Seen Under Pressure Amid Weak Farmer Sentiment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the Genenta Science logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$0.6199
Prev Close	$0.6588
Open	$0.6998
Dividend Yield	0.00%
50-Day Moving Average	$0.9061
Beta	0.35
Avg. Volume	62,512.01
PE Ratio	-1.77

52-Week High	$10.00
52-Week Low	$0.55
Market Capitalization	$31.77M
EPS (Annual)	-$0.3739
Price to Book	0.60
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

GNTA Fundamentals